Galmed (GLMD) director Amir Poshinski details shares, RSUs and options

Rhea-AI Filing Summary

Galmed Pharmaceuticals director Amir Poshinski has reported his initial ownership position in the company. The filing shows direct holdings of ordinary shares, multiple restricted share unit grants that vest over several dates through 2028, and stock options over 111 and 166 ordinary shares at exercise prices of 558.0000 and 2080.8000, expiring in 2031 and 2028 respectively.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Poshinski Amir

Role Director

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Restricted Share Units	--	--	--
holding	Restricted Share Units	--	--	--
holding	Restricted Share Units	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 111 shares (Direct); Ordinary Shares — 11,042 shares (Direct); Restricted Share Units — 1,042 shares (Direct)

Footnotes (1)

1. These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service. These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service. These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Poshinski Amir

(Last) (First) (Middle)

C/O MEITAR LAW OFFICES *

16 ABBA HILLEL SILVER RD.

(Street)

RAMAT GAN 5250608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Galmed Pharmaceuticals Ltd. [ GLMD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	11,042	D
Restricted Share Units	1,042(1)	D
Restricted Share Units	11,666(2)	D
Restricted Share Units	12,500(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares	07/15/2021	07/15/2031	Ordinary Shares	111	$558	D
Options to Purchase Ordinary Shares	07/10/2018	07/10/2028	Ordinary Shares	166	$2,080.8	D

Explanation of Responses:

1. These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.

2. These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.

3. These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

	/s/ Amir Poshinski	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Amir Poshinski’s Form 3 filing for GLMD report?

The filing reports Amir Poshinski’s initial ownership in Galmed Pharmaceuticals Ltd. (GLMD), including ordinary shares, restricted share units with scheduled vesting, and stock options over specified numbers of ordinary shares at defined exercise prices and expiration dates.

Does the GLMD Form 3 for Amir Poshinski show any share purchases or sales?

No new purchases or sales are shown. The Form 3 records existing holdings—ordinary shares, restricted share units, and option awards—rather than new buy or sell transactions, providing a baseline of Poshinski’s equity position as a company director.

What stock options does Amir Poshinski hold in Galmed Pharmaceuticals (GLMD)?

He holds options to purchase ordinary shares with underlying amounts of 111 shares at 558.0000 and 166 shares at 2080.8000 per share, expiring in 2031 and 2028 respectively, according to the filing’s derivative position summary.

How are Amir Poshinski’s restricted share units in GLMD scheduled to vest?

The filing shows multiple restricted share unit grants that vest on specific dates from August 7, 2026 through August 26, 2028, generally in installments and subject to Poshinski’s continued service with Galmed Pharmaceuticals Ltd.

Why is Amir Poshinski’s Form 3 disclosure for GLMD important to investors?

Form 3 provides a baseline of an insider’s equity stake when they become subject to reporting rules. For GLMD, it shows how much exposure director Amir Poshinski has through shares, options, and restricted share units tied to Galmed’s future performance.